XML 38 R24.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - AstraZeneca Agreements [Member] - USD ($) $ in Millions |  | 3 Months Ended | 6 Months Ended
--- | --- | --- | ---
Jul. 30, 2013 | Jun. 30, 2016 | Dec. 31, 2015 | Jun. 30, 2015 | Jun. 30, 2016
U.S./RoW [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Expected upfront, non-contingent and time-based payments | $ 374.0 |  |  |  |
Upfront, non-contingent and time-based payments received |  | $ 62.0 |  |  |
Development and regulatory approval milestones | 550.0 |  |  |  |
Commercial sales milestone | 325.0 |  |  |  |
Shared development costs |  |  | $ 233.0 |  |
Additional consideration based on net sales description |  |  |  |  | Low 20% range
U.S./RoW [Member] | FibroGen, Inc. [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Shared development costs |  |  | $ 116.5 |  |
U.S./RoW [Member] | Development Milestones [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Receipt of development milestone payment |  |  |  | $ 15.0 |
China [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Development and regulatory approval milestones | 161.0 |  |  |  |
Commercial sales milestone | 167.5 |  |  |  |
Proceeds from upfront payments | 28.2 |  |  |  |
Contingent payment | $ 20.0 |  |  |  |

X
- Definition The amount of additional consideration based on net sales of product as defined under a collaboration agreement. + References No definition available. + Details
Name: | fgen_AdditionalConsiderationBasedOnNetSales
Namespace Prefix: | fgen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of milestone payments related to commercial sales under the collaborative agreement. + References No definition available. + Details
Name: | fgen_CommercialSalesMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of contingent payments provided for under the collaboration agreement. + References No definition available. + Details
Name: | fgen_ContingentPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement. + References No definition available. + Details
Name: | fgen_DevelopmentAndRegulatoryApprovalMilestones
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development milestone payment received. + References No definition available. + Details
Name: | fgen_DevelopmentMilestonePaymentReceived
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the total amount of expected non-contingent upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ExpectedProceedsFromUpfrontNonContingentAndTimeBasedPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the total amount of development costs that will be shared under collaborative agreement. + References No definition available. + Details
Name: | fgen_SharedDevelopmentCosts
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=fgen_FibroGenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |